Your browser doesn't support javascript.
loading
App-based assessment of patient-reported outcomes in the Molecular Tumor Board in the Center for Personalized Medicine-(TRACE).
Dörner, Lorenz; Grosse, Lucia; Stange, Felix; Hille, Hanni; Kurz, Sylvia; Becker, Hannes; Volkmer, Sebastian; Hippler, Melina; Rieger, David; Bombach, Paula; Rieger, Johannes; Weinert, Lina; Svensson, Laura; Anders, Carolin; Cekin, Sila; Paulsen, Frank; Öner, Öznur; Ruhm, Kristina; Malek, Holly Sundberg; Möller, Yonne; Tatagiba, Marcos; Wallwiener, Markus; Eckert, Nils; Escher, Pascal; Pfeifer, Nico; Forschner, Andrea; Bauer, Armin; Zips, Daniel; Bitzer, Michael; Malek, Nisar; Gani, Cihan; Tabatabai, Ghazaleh; Renovanz, Mirjam.
Afiliación
  • Dörner L; Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Grosse L; Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Stange F; Center for Personalized Medicine Tübingen, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Hille H; Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Kurz S; Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Becker H; Center for Personalized Medicine Tübingen, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Volkmer S; Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Hippler M; Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Rieger D; Center for Personalized Medicine Tübingen, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Bombach P; Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Rieger J; Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Weinert L; Center for Personalized Medicine Tübingen, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Svensson L; Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Anders C; Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Cekin S; Center for Personalized Medicine Tübingen, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Paulsen F; Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Öner Ö; Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Ruhm K; Center for Personalized Medicine Tübingen, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Malek HS; Department of Neurosurgery, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Möller Y; Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Tatagiba M; Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Wallwiener M; Center for Personalized Medicine Tübingen, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Eckert N; Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Escher P; Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Pfeifer N; Center for Personalized Medicine Tübingen, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Forschner A; Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Bauer A; Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Zips D; Center for Personalized Medicine Tübingen, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Bitzer M; Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Malek N; Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Gani C; Center for Personalized Medicine Tübingen, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Tabatabai G; Department of Neurology & Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University of Tübingen, Tübingen, Germany.
  • Renovanz M; Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard Karls University of Tübingen, Tübingen, Germany.
Neurooncol Pract ; 11(3): 336-346, 2024 Jun.
Article en En | MEDLINE | ID: mdl-38737615
ABSTRACT

Background:

Biomarker-based therapies are increasingly used in cancer patients outside clinical trials. Systematic assessment of patient-reported outcomes (PRO) is warranted to take patients' perspectives during biomarker-based therapies into consideration. We assessed the feasibility of an electronic PRO assessment via a smartphone application.

Methods:

An interdisciplinary expert panel developed a smartphone application based on symptom burden and health-related quality of life (HRQoL) metrics reported in a retrospective analysis of 292 neuro-oncological patients. The app included validated assessments of health-related quality of life (HRQoL), the burden of symptoms, and psychological stress. Feasibility and usability were tested in a pilot study. Semi-structured interviews with patients and health care professionals (HCP) were conducted, transcribed, and analyzed according to Mayring´s qualitative content analysis. Furthermore, we assessed compliance and descriptive data of ePROs.

Results:

A total of 14 patients have been enrolled, (9 female, 5 male). A total of 4 HCPs, 9 patients, and 1 caregiver were interviewed regarding usability/feasibility. The main advantages were the possibility to complete questionnaires at home and comfortable implementation in daily life. Compliance was high, for example, 82% of the weekly distributed NCCN distress thermometer questionnaires were answered on time, however, with interindividual variability. We observed a median distress score of 5 (range 0-10, 197 results, n = 12, weekly assessed) and a median Global health score of 58.3 according to the EORTC QLQ-C30 instrument (range 16.7-100, 77 results, n = 12, monthly assessed).

Conclusions:

This pilot study proved the feasibility and acceptance of the app. We will therefore expand its application during biomarker-guided therapies to enable systematic PRO assessments.
Palabras clave

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Neurooncol Pract Año: 2024 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Colección: 01-internacional Idioma: En Revista: Neurooncol Pract Año: 2024 Tipo del documento: Article País de afiliación: Alemania